Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.20 and traded as low as $0.1635. Northwest Biotherapeutics shares last traded at $0.1656, with a volume of 1,941,472 shares changing hands.

Northwest Biotherapeutics Stock Down 3.3%

The firm has a market cap of $276.92 million, a price-to-earnings ratio of -0.01 and a beta of -0.61. The business’s fifty day moving average is $0.17 and its two-hundred day moving average is $0.20.

Get Northwest Biotherapeutics alerts:

Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $0.81 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Northwest Biotherapeutics stock. Compass Financial Management LLC acquired a new stake in Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,215,500 shares of the biotechnology company’s stock, valued at approximately $227,000. Compass Financial Management LLC owned about 0.07% of Northwest Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 0.04% of the stock is owned by hedge funds and other institutional investors.

About Northwest Biotherapeutics

(Get Free Report)

Northwest Biotherapeutics, Inc is a biotechnology company focused on developing personalized cancer immunotherapies. Its lead platform uses a patient’s own dendritic cells, which are immune cells collected from the patient and prepared to recognize and stimulate an immune response against tumor tissue.

The company’s principal investigational product is DCVax-L, an autologous dendritic-cell vaccine designed for patients with glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also developed DCVax-Direct, an investigational treatment intended for injection directly into inoperable solid tumors.

Further Reading

• Five stocks we like better than Northwest Biotherapeutics
• J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
• 2 Stocks Breaking Out Post-FOMC With One Thing in Common
• Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
• These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons

Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.